Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Stock Information for Agenus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Agenus Inc.

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
Kuehn Law Encourages Investors of Agenus Inc. to Contact Law Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.